Emergent BioSolutions Inc. (EBS)

Oncology Corporate Profile

Stock Performance

29.1000
0.0000

HQ Location

2273 Research Boulevard, Suite 400
Rockville, MD 20850

Company Description

Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent's marketed and investigational products target infectious diseases, oncology and autoimmune disorders.

Website: http://www.emergentbiosolutions.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
otlertuzumabCD37 protein inhibitor)Chronic Lymphocytic Leukemia (CLL)II
TRU-016 (+ bendamustine)anti-CD37 IgG fusion proteinNon-Hodgkin?s Lymphoma (NHL)II
HuMax-CD4_ / zanolimumabimmunosuppressiveCutaneous T-cell Lymphoma (CTCL)I
HuMax-CD4_ / zanolimumabimmunosuppressivePeripheral T-cell Lymphoma (PTCL)I
MOR209/ES414anti-PSMA/anti-CD3 bi-specific antibodyProstate cancerPreclinicalMorphosys

View additional information on product candidates here »

Source


http://www.emergentbiosolutions.com/

Recent News Headlines

Emergent BioSolutions Awarded $100 Million BARDA Contract for BioThrax Deliveries to the Strategic National Stockpile

3/17/2017 11:00 am

[GlobeNewswire] - GAITHERSBURG, Md., March 17, 2017-- Emergent BioSolutions Inc. today announced that it has signed a two-year contract with the Biomedical Advanced Research and Development Authority, a division within ...

Blog Coverage Galapagos Announced New Phase-II Studies Led by Filgotinib Collaboration Partner Gilead Sciences

3/13/2017 12:01 pm

[Accesswire] - Upcoming AWS Coverage on Emergent BioSolutions Post-Earnings Results LONDON, UK / ACCESSWIRE / March 13, 2017 / Active Wall St. blog coverage looks at the headline from Galapagos N.V. (NASDAQ: GLPG ) as ...

Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2016 Financial Results; Reaffirms 2017 Guidance and Provides 2020 Goals

2/23/2017 09:01 pm

[GlobeNewswire] - GAITHERSBURG, Md., Feb. 23, 2017-- Emergent BioSolutions Inc. reported financial results for the quarter and twelve months ended December 31, 2016.. The presentation of Emergent’ s financial performance ...

Emergent BioSolutions Receives BARDA Task Order Valued at Up to $30.5 Million to Develop Viral Hemorrhagic Fever Therapeutics

2/13/2017 12:00 pm

[GlobeNewswire] - GAITHERSBURG, Md., Feb. 13, 2017-- Emergent BioSolutions Inc. today announced that it has received a task order from the Biomedical Advanced Research and Development Authority valued at up to $30.5 million ...

Emergent BioSolutions to Release Fourth Quarter and Full Year 2016 Financial Results and Conduct a Conference Call on February 23, 2017

2/9/2017 12:00 pm

[GlobeNewswire] - GAITHERSBURG, Md., Feb. 09, 2017-- Emergent BioSolutions Inc. will host a conference call on Thursday, February 23, 2017 at 5:00 pm to discuss the financial results for the fourth quarter and full twelve ...

Emergent BioSolutions Initiates NIAID-Funded Phase 1b Clinical Study to Evaluate Broad-Spectrum Antiviral UV-4B for Dengue

2/1/2017 12:00 pm

[GlobeNewswire] - GAITHERSBURG, Md., Feb. 01, 2017-- Emergent BioSolutions Inc. today announced the initiation of a Phase 1 b multiple ascending dose study to evaluate the safety and tolerability of UV-4B, the company’ ...